Design of Insulin Variants for Improved Treatment of Diabetes - Peptide and Protein Design for Biopharmaceutical Applications - page 274

[8] S. Heller, P. Kozlovski and P. Kurtzhals, Insulin's 85th anniversary - An enduring
medical miracle, Diab. Res. Clin. Pract ., 78, 149-158 (2007).
[9] J. C. Henquin, Triggering and amplifying pathways of regulation of insulin secretion
by glucose, Diabetes , 49, 1751-1760 (2000).
[10] J. J. Holst, Glucagon-like peptide-1: From extract to agent. The Claude Bernard
Lecture, 2005, Diabetologia , 49, 253-260 (2006).
[11] D. F. Steiner, Proinsulin and the biosynthesis of insulin, N. Engl. J. Med ., 280,
1106-1113 (1969).
[12] A. Luyckx, The role of glucagon in hyperglycemia. A review, Diabetes Metab ., 1,
201-208 (1975).
[13] H. Peng and W. Hagopian, Environmental factors in the development of Type 1
diabetes, Rev. Endocr. Metab. Disord ., 7, 149-162 (2006).
[14] Z. T. Bloomgarden, Insulin resistance: Current concepts, Clin. Ther ., 20, 216-231
(1998).
[15] N. Ahmed and P. J. Thornalley, Advanced glycation endproducts: What is their
relevance to diabetic complications?, Diab. Obes. Metab ., 9, 233-245 (2007).
[16] M. Brownlee, Biochemistry and molecular cell biology of diabetic complications,
Nature , 414, 813-820 (2001).
[17] P. Ulrich and A. Cerami, Protein glycation, diabetes, and aging, Rec. Progr. Horm.
Res ., 56, 1-22 (2001).
[18] R. Sicree and J. Shaw, Type 2 diabetes: An epidemic or not, and why it is happening,
Diab. Metab. Syndr. Clin. Res. Rev ., 1, 75-81 (2007).
[19] P. J. Guillausseau, Influence of oral antidiabetic drugs compliance on metabolic control
in type 2 diabetes. A survey in general practice, Diabetes Metab ., 29, 79-81 (2003).
[20] S. Heinzl, Early insulin therapy in diabetis mellitus lowers the cardiovascular risk,
Med. Monats. Pharm ., 30, 160-161 (2007).
[21] A. Liebl, The when and how of insulin initiation in type 2 diabetes, Curr. Med. Res.
Opin ., 23, 129-132 (2007).
[22] L. Arendt-Nielsen, H. Egekvist and P. Bjerring, Pain following controlled cutaneous
insertion of needles with different diameters, Somatos. Mot. Res ., 23, 37-43 (2006).
[23] J. C. Scheller and J. A. Galloway, The development of the insulin unit, Am. J. Pharm.
Sci. Supp. Publ. Health , 147, 29-32 (1975).
[24] A. Bayes-Genis, C. A. Conover and R. S. Schwartz, The insulin-like growth factor
axis - A review of atherosclerosis and restenosis, Circ. Res ., 86, 125-130 (2000).
[25] E. Bonora, Antidiabetic medications in overweight/obese patients with type 2
diabetes: Drawbacks of current drugs and potential advantages of incretin-based
treatment on body weight, Int. J. Clin. Pract ., 61, 19-28 (2007).
[26] Portable blood glucose monitors, Health Devices , 29, 201-232 (2000).
[27] M. Procopiou, HbA1c: Review and recent developments, Rev. Med. Suis ., 2,
1473-1476 (2006).
[28] J. H. Simmons, K. K. Mcfann, A. C. Brown, A. Rewers, E. Cruz and G. J. Klingensmith,
Achieving pediatric ADA HbA1c goals: Insulin pump therapy vs injection therapy,
Diabetes , 55,A413(2006).
[29] H. S. Seltzer, Drug-induced hypoglycemia. A review of 1418 cases, Endo. Metab.
Clin. N. Am ., 18, 163-183 (1989).
[30] G. H. Murata, W. C. Duckworth, R. M. Hoffman, C. S. Wendel, M. J. Mohler and
J. H. Shah, Hypoglycemia in type 2 diabetes: A critical review, Biomed. Pharm ., 58,
551-559 (2004).